PHASE I TRIAL OF SUNITINIB PLUS IMATINIB IN PATIENTS WITH METASTATIC OR UNRESECTABLE GASTROINTESTINAL STROMAL TUMORS (GIST)

被引：0
|
作者：
Lopez Pousa, A. [1 ]
Paz-Ares, L. [2 ]
Pericay, C. [3 ]
Garcia Del Muro, X. [4 ]
Flor, M. J. [5 ]
机构：
[1] Hosp Sta Creu & St Pau, Barcelona, Spain
[2] Hosp Virgen del Roc, Seville, Spain
[3] Corp Sanitaria Parc Tauli Inst Univ, Sabadell, Spain
[4] Inst Catala Oncol, Lhospitalet De Llobregat, Spain
[5] Hosp Virgen del Rocio, Oncol Serv, Seville, Spain
来源：
ANNALS OF ONCOLOGY | 2012年 / 23卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：235 / 235
页数：1
相关论文
共 50 条
  • [31] Patterns of Care, Prognosis, and Survival in Patients with Metastatic Gastrointestinal Stromal Tumors (GIST) Refractory to First-Line Imatinib and Second-Line Sunitinib
    Antoine Italiano
    Angela Cioffi
    Paola Coco
    Robert G. Maki
    Patrick Schöffski
    Piotr Rutkowski
    Axel Le Cesne
    Florence Duffaud
    Antoine Adenis
    Nicolas Isambert
    Emmanuelle Bompas
    Jean-Yves Blay
    Paolo Casali
    Mary Louise Keohan
    Maud Toulmonde
    Cristina R. Antonescu
    Maria Debiec-Rychter
    Jean-Michel Coindre
    Binh Bui
    Annals of Surgical Oncology, 2012, 19 : 1551 - 1559
  • [32] A phase I study of nilotinib alone and in combination with imatinib in patients (PTS) with imatinib-resistant gastrointestinal stromal tumors (GIST) -: Study update
    Reichardt, Peter
    Casali, Paolo G.
    Blay, Jean-Yves
    von Mehren, Margaret
    Schoffski, Patrick
    Tanaka, Chiaki
    Jalaluddin, Muhammad
    Veronese, Maria Luisa
    Demetri, George D.
    ANNALS OF ONCOLOGY, 2006, 17 : 138 - 138
  • [33] A phase I study of AMN107 alone and in combination with imatinib in patients (pts) with imatinib-resistant gastrointestinal stromal tumors (GIST).
    Reichardt, P.
    Casali, P. G.
    Blay, J.
    Von Mehren, M.
    Schoffski, P.
    Hosseinzadeh, S.
    Tanaka, C.
    Gsponer, T.
    Veronese, M. L.
    Demetri, G. D.
    JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (18) : 531S - 531S
  • [34] Activity of sorafenib (SOR) in patients (pts) with imatinib (IM) and sunitinib (SU)-resistant (RES) gastrointestinal stromal tumors (GIST): A phase II trial of the University of Chicago Phase II Consortium
    Wiebe, L.
    Kasza, K. E.
    Maki, R. G.
    D'Adamo, D. R.
    Chow, W. A.
    Wade, J. L., III
    Agamah, E.
    Stadler, W. M.
    Vokes, E. E.
    Kindler, H. L.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [35] Efficacy and Safety of Regorafenib in Patients With Metastatic and/or Unresectable GI Stromal Tumor After Failure of Imatinib and Sunitinib: A Multicenter Phase II Trial
    George, Suzanne
    Wang, Qian
    Heinrich, Michael C.
    Corless, Christopher L.
    Zhu, Meijun
    Butrynski, James E.
    Morgan, Jeffrey A.
    Wagner, Andrew J.
    Choy, Edwin
    Tap, William D.
    Yap, Jeffrey T.
    Van den Abbeele, Annick D.
    Manola, Judith B.
    Solomon, Sarah M.
    Fletcher, Jonathan A.
    von Mehren, Margaret
    Demetri, George D.
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (19) : 2401 - 2407
  • [36] Randomized phase III trial of imatinib (IM) rechallenge versus placebo in patients (pts) with metastatic and/or unresectable gastrointestinal stromal tumor (GIST) after failure of at least both IM and sunitinib (SU): Right study.
    Kang, Yoon-Koo
    Ryu, Min-Hee
    Ryoo, Baek-Yeol
    Kim, Hyun Jin
    Lee, Jong Jin
    Yoo, Changhoon
    Nam, Byung-Ho
    Ramaiya, Nikhil
    Jagannathan, Jyothi Priya
    Demetri, George D.
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [37] Results of Phase II trial of AUY922, a novel heat shock protein inhibitor in patients with metastatic gastrointestinal stromal tumor (GIST) and imatinib and sunitinib therapy.
    Chiang, Nai-Jung
    Yeh, Kun-Huei
    Chiu, Chang-Fang
    Chen, Jen-Shi
    Yen, Chueh-Chuan
    Lee, Kuan-Der
    Lin, Yu-Lin
    Bai, Li-Yuan
    Chen, Ming-Huang
    Lin, Jen-Shi
    Yang, Youngsen
    Rau, Kun-Ming
    Hsiao, Hui-Hua
    Shan, Yan-Shen
    Chen, Li-Tzong
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (04)
  • [38] Approval summary: Imatinib mesylate in the treatment of metastatic and/or unresectable malignant gastrointestinal stromal tumors
    Dagher, R
    Cohen, M
    Williams, G
    Rothmann, M
    Gobburu, J
    Robbie, G
    Rahman, A
    Chen, G
    Staten, A
    Griebel, D
    Pazdur, R
    CLINICAL CANCER RESEARCH, 2002, 8 (10) : 3034 - 3038
  • [39] Imatinib discontinuation in patients with metastatic gastrointestinal stromal tumors (GISTs)
    de Pas, Tommaso
    Biffi, Roberto
    Mazzarol, Giovanni
    Della Vigna, Paolo
    Travaini, Laura
    Curigliano, Giuseppe
    Formica, Vincenzo
    de Braud, Filippo
    ANNALS OF ONCOLOGY, 2004, 15 : 201 - 201
  • [40] Approval Summary: Imatinib Mesylate in the Treatment of Metastatic and/or Unresectable Malignant Gastrointestinal Stromal Tumors
    Cohen, Martin H.
    Farrell, Ann
    Justice, Robert
    Pazdur, Richard
    ONCOLOGIST, 2009, 14 (02): : 174 - 180
12345